TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11940541
Drug: Enoxaparin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.3 to 0.75 mg/kg subcutaneously every 12 hours +/- initial intravenous bolus of 30 mg)
Study: 11940541
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) (bolus 60 U/kg; infusion 12 U/kg per hour)
Study: 11940541
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) (bolus 40 U/kg; infusion 7 U/kg per hour)
Study: 1914378
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg galanthamine hydrobromide intravenous infusion for 30 minutes
Study: 1914378
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg galanthamine hydrobromide intravenous infusion for 30 minutes
Study: 1914378
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg single oral dose of galanthamine
Study: 6140230
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg metoprolol (beta‐1‐selective blockade)
Study: 6140230
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bupranolol (nonselective beta‐blockade)
Study: 6140230
Drug: Both beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both beta-blockers (metoprolol and bupranolol)
Study: 27860410
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg every 2 weeks
Study: 26299550
Drug: Midazolam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2.5 mg)
Study: 26299550
Drug: Midazolam-alfentanil combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-alfentanil combination (1 mg midazolam and 5 μg/kg alfentanil)
Study: 26299550
Drug: Propofol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5 mg/kg intravenous bolus)
Study: 25030782
Drug: High-fructose (HF)
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose (HF) sweetened beverage (710 mL/d, 50 g fructose/d, 15 g glucose/d)
Study: 25030782
Drug: High-glucose (HG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-glucose (HG) sweetened beverage (710 mL/d, 50 g glucose/d, 15 g fructose/d)
Study: 20033075
Drug: Aliskiren 150-300
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150-300 mg per day
Study: 20033075
Drug: Ramipril 5-10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5-10 mg per day
Study: 18005484
Drug: High-fibre meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fibre meal (HFM) (15 g of fibre)
Study: 18005484
Drug: Low-fibre meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fibre meal (LFM) (3 g of fibre)
Study: 12385542
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg orally once daily
Study: 12385542
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg orally once daily with propranolol 40 mg orally twice daily
Study: 1514500
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nifedipine
Study: 28007005
Drug: 0.01% oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% oral capsaicin gel
Study: 28007005
Drug: 0.025% oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% oral capsaicin gel
Study: 21489699
Drug: 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/kg CRH infusion
Study: 19407292
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 20 ml 0.5% bupivacaine (group 1)
Study: 19407292
Drug: Portal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal infiltration of 20 ml 0.5% bupivacaine (group 2)
Study: 12518376
Drug: L-asparaginase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase therapy
Study: 11063156
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg daily for 6 months
Study: 9067278
Drug: Plasma folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma folate deficiency (<3 ng/ml)
Study: 7933504
Drug: Buprenorphine suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine suppository (0.4 mg) preoperative administration (group A1)
Study: 7933504
Drug: Buprenorphine suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine suppository (0.4 mg) postoperative administration (group A2)
Study: 7933504
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 0.1 mg of buprenorphine during surgery and postoperative administration of buprenorphine suppository (group A3)
Study: 28169080
Drug: music-plus-massage group
Approvals — FDA: no, EMA: no, PMDA: no
Description: music-plus-massage group (n=60) receiving a combination of their favorite songs and Swedish massage
Study: 19393768
Drug: PPA administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA administration with educational module
Study: 19393768
Drug: Initial explanation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial explanation and baseline PPA administration
Study: 16905783
Drug: 3-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-drug regimen (Zidovudine/lamivudine plus efavirenz)
Study: 16905783
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen (Zidovudine/lamivudine/abacavir plus efavirenz)
Study: 16905783
Drug: 3-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-drug regimen
Study: 15592270
Drug: Metronidazole 0.75%
Normalized name: METRONIDAZOLE 0.75% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 0.75% gel (37.5 mg metronidazole per dose), once nightly for 5 nights
Study: 15592270
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg plus nystatin 100,000 U ovules, once nightly for 5 nights
Study: 11485952
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate at a dose of 200 microg/day
Study: 11485952
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate at doses of 100-250 microg/day
Study: 11485952
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate at a dose of around 500 microg/day
Study: 9441148
Drug: Induced labor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced labor (artificial rupture of membranes and oxytocin infusion)
Study: 7964952
Drug: Five-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug regimen (etoposide, thioguanine, dexamethasone, daunorubicin, and cytarabine)
Study: 7964952
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy consolidation
Study: 2444802
Drug: Metoprolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (beta 1-selective antagonist)
Study: 2444802
Drug: Labetalol (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (combined alpha/beta-receptor blockade)
Study: 25539791
Drug: LY40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY40 mg BID
Study: 25539791
Drug: LY80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY80 mg BID
Study: 25539791
Drug: Risperidone (RIS)
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone (RIS) 2 mg BID
Study: 20409331
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Methylprednisolone + 10 mg Lidocaine
Study: 20409331
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Methylprednisolone + 10 mg Lidocaine
Study: 20409331
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline + 10 mg Lidocaine (placebo)
Study: 18952164
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day vitamin C
Study: 12717099
Drug: Allopurinol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (400 mg) administered orally just after admission (60 min before reperfusion)
Study: 22102633
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no allopurinol treatment)
Study: 12717099
Drug: Allopurinol treatment
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol treatment group
Study: 9459673
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (15 sessions)
Study: 8333258
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid viscous eye drops 1% given twice daily
Study: 8333258
Drug: Chloramphenicol eye
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol eye drops 0.5% given 6 times daily
Study: 3511401
Drug: High-dosage trihexyphenidyl
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage trihexyphenidyl (30 mg)
Study: 30194737
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program plus 1% chlorhexidine varnish monthly application
Study: 30194737
Drug: Current oral
Normalized name: black currant oil Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current oral hygiene practice (control)
Study: 18947472
Drug: Control (pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pulse intravenous infusion of cyclophosphamide (CTX) plus prednisone)
Study: 18947472
Drug: Control (pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pulse intravenous infusion of cyclophosphamide (CTX))
Study: 12598347
Drug: Tamoxifen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen alone (160 mg day 1, then 20 mg/day for 5 years)
Study: 12598347
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus tamoxifen (20 mg/day for 5 years)
Study: 30688410
Drug: Preprandial metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprandial metformin administration (500-1,000 mg)
Study: 30688410
Drug: Postprandial metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial metformin administration (500-1,000 mg)
Study: 25064164
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) 100 mg/kg/dose administered every 6 hours until delivery
Study: 25064164
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) 100 mg/kg/dose
Study: 25064164
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) 12.5-25 mg/kg/dose administered every 12 hours for 5 doses
Study: 25064164
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered within 4 hours of CA diagnosis
Study: 17593161
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily for 12 weeks
Study: 11943936
Drug: Desmopressin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (300 microg nasal inhalation)
Study: 9951357
Drug: Intensive acupuncture
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive acupuncture treatment (25 sessions over 2 months, 30 minutes each)
Study: 7844609
Drug: IL-1 beta
Normalized name: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein
DrugBank: Goflikicept (DB16396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1 beta (0.005 to 0.2 micrograms/kg/d) combined with IL-2 (0.1 mg/m2/d)
Study: 7844609
Drug: IL-1 beta
Normalized name: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein
DrugBank: Goflikicept (DB16396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1 beta (0.005 to 0.05 micrograms/kg/d) combined with IL-2 (0.1 mg/m2/d)
Study: 7844609
Drug: IL-1 beta
Normalized name: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein
DrugBank: Goflikicept (DB16396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1 beta (0.1 to 0.2 micrograms/kg/d) combined with IL-2 (0.1 mg/m2/d)
Study: 2309545
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine (75 mg)
Study: 393363
Drug: Minocycline 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 300 mg
Study: 393363
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 g and probenecid 1 g
Study: 31770617
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment with rifapentine and isoniazid
Study: 23499158
Drug: Sofosbuvir 200
Normalized name: sofosbuvir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 200 mg + peginterferon + ribavirin
Study: 23499158
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg + peginterferon + ribavirin
Study: 23499158
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg + peginterferon + ribavirin (cohort B)
Study: 19585548
Drug: High-dose ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodeoxycholic acid (UDCA) (28-30 mg/kg/day)
Study: 19585548
Drug: High-dose ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodeoxycholic acid (UDCA)
Study: 17919823
Drug: Dacarbazine monotherapy
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine monotherapy
Study: 17919823
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (alone or in combination)
Study: 15372386
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine in 20 mL of 0.9% NaCl solution (5 mL of solution per point) 10 minutes before the operation (Group M)
Study: 15372386
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% bupivacaine (Group B)
Study: 15372386
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine in 20 mL of 0.25% bupivacaine (Group M+B)
Study: 15372386
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.9% NaCl (Group S)
Study: 15372386
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.9% NaCl with 2 mg of subcutaneous morphine 10 minutes before surgery (Group S+M)
Study: 18980474
Drug: Thyrotropin releasing
Normalized name: Thyrotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin releasing hormone
Study: 1392111
Drug: Topical lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lithium succinate ointment (LSO)
Study: 4002806
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg M/day
Study: 4002806
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg M/day
Study: 27153158
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of 9 µg of hemagglutinin (HA) per strain
Study: 27153158
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 15 µg of HA per strain
Study: 27153158
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection
Study: 10217608
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: 24461315
Drug: Cinnamon (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (1500 mg daily)
Study: 24461315
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules daily)
Study: 21049063
Drug: 20 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg/day of paromomycin for 21 days
Study: 21049063
Drug: 15 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/day of paromomycin for 28 days
Study: 17984140
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg/kg on the first day followed by 50 mg/kg/day for three days
Study: 11958351
Drug: Compound cue
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound cue AT followed by an outcome (AT+)
Study: 12551863
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg BID)
Study: 8961043
Drug: Fluoxetine (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (not specified dosage or duration)
Study: 1761079
Drug: Eltoprazine HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Eltoprazine (DB12883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltoprazine HCl 5, 10, 20 mg
Study: 1761079
Drug: Eltoprazine HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Eltoprazine (DB12883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltoprazine HCl 30 mg
Study: 31980871
Drug: Diltiazem gel
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem gel 2%
Study: 30922355
Drug: Binafuxi granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binafuxi granules (high-dose group)
Study: 30922355
Drug: Binafuxi granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binafuxi granules (low-dose group)
Study: 27601545
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy and 6 months of ADT
Study: 19151384
Drug: Real therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real therapy
Study: 17474541
Drug: Test syrup
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test syrup containing 15 mg dextromethorphan hydrobromide, 7.5 mg doxylamine succinate, 600 mg paracetamol, and 8 mg ephedrine sulfate (Group T)
Study: 17474541
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup (Group P)
Study: 17474541
Drug: Test syrup
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test syrup (Group T)
Study: 348553
Drug: Milk B
Normalized name: Milk bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk B (12.5 g of lactose)
Study: 348553
Drug: Milk C
Normalized name: Milk casein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk C (37.5 g of lactose)
Study: 16164475
Drug: Acupressure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure therapy
Study: 21937521
Drug: Hyperthermia and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia and Sham treatment
Study: 17466110
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behaviour therapy
Study: 17466110
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behaviour therapy
Study: 11529210
Drug: Prone positioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prone positioning for six or more hours daily for 10 days
Study: 11529210
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in the supine position
Study: 9096189
Drug: Rifabutin in
Normalized name: Product containing rifabutin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin in combination with a macrolide antibiotic (clarithromycin or azithromycin)
Study: 8329260
Drug: S(+)‐ketamine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine 1 mg/kg body weight
Study: 8329260
Drug: Racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic ketamine 2 mg/kg body weight
Study: 30509638
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein meal with phosphorus (500 mg)
Study: 30509638
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein meal with phosphorus (500 mg)
Study: 24713309
Drug: Serial weekly
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial weekly transabdominal amnioinfusion (AI)
Study: 21143403
Drug: Modified-release paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release paracetamol (PEx) 80 mg/kg
Study: 21143403
Drug: Immediate-release paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release paracetamol (APAP-IR) 80 mg/kg